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Introduction: The primary aim of this study was to determine whether hypophosphatemia during continuous
veno-venous hemofiltration (CVVH) is associated with the global outcome of critically ill patients with acute kidney
injury (AKI).
Methods: 760 patients diagnosed with AKI and had received CVVH therapy were retrospectively recruited. Death
during the 28-day period and survival at 28 days after initiation of CVVH were used as endpoints. Demographic and
clinical data including serum phosphorus levels were recorded along with clinical outcome. Hypophosphatemia
was defined according to the colorimetric method as serum phosphorus levels < 0.81 mmol/L (2.5 mg/dL), and
severe hypophosphatemia was defined as serum phosphorus levels < 0.32 mmol/L (1 mg/dL). The ratio of CVVH
therapy days with hypophosphatemia over total CVVH therapy days was calculated to reflect the persistence of
hypophosphatemia.
Results: The Cox proportional hazard survival model analysis indicated that the incidence of hypophosphatemia or
even severe hypophosphatemia was not associated with 28-day mortality independently (p = 0.700). Further
analysis with the sub-cohort of patients who had developed hypophosphatemia during the CVVH therapy period
indicated that the mean ratio of CVVH therapy days with hypophosphatemia over total CVVH therapy days was
0.58, and the ratio independently associated with the global outcome. Compared with the patients with low ratio
(< 0.58), those with high ratio (≥ 0.58) conferred a 1.451-fold increase in 28-day mortality rate (95% CI 1.103–1.910,
p = 0.008).
Conclusions: Hypophosphatemia during CVVH associated with the global clinical outcome of critically ill patients
with AKI. The ratio of CVVH therapy days with hypophosphatemia over total CVVH therapy days was independently
associated with the 28-day mortality, and high ratio conferred higher mortality rate.Introduction
Hypophosphatemia is one of the frequently encountered
electrolyte disorders in critically ill patients, with a pre-
valence ranging from 20% to 40% [1-4] and even rea-
ching 80% in septic patients [5]. Because the common
mechanism in hypophosphatemia-caused complications
is impaired energy metabolism, hypophosphatemia has
also been described as a metabolic disturbance leading
to cellular dysfunction in multiple organ systems [6].* Correspondence: chenjianghua@zju.edu.cn
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reproduction in any medium, provided the orTherefore, hypophosphatemia may lead to some serious
clinical problems, such as respiratory muscle dysfunction
[7,8], decreased myocardial contractility [9], ventricular
tachycardia [10] and neuromuscular disturbances [11,12].
Many studies have shown an association between hypo-
phosphatemia and increased mortality [13-15]. However,
it remains unclear whether hypophosphatemia actually
contributes to mortality or is merely a marker for severity
of illness.
Three main mechanisms lead to hypophosphatemia:
decreased intestinal absorption, increased renal excre-
tion and internal redistribution of inorganic phosphate.
The main causes of hypophosphatemia in critically illd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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state, malnutrition, respiratory alkalosis and diabetic
ketoacidosis [6]. Renal replacement therapy may also
lead to hypophosphatemia, particularly for a prolonged
period [16-18]. The incidence of hypophosphatemia was
reported to range from 54.0% to 65.1% in the Ran-
domized Evaluation of Normal vs. Augmented Level
(RENAL) Replacement Therapy Trial and from 10.9% to
17.6% in the VA/NIH Acute Renal Failure Trial Network
(ATN) Study [19,20]. Because renal replacement therapy
is one of the most widely used methods to treat critical
illness, especially acute kidney injury (AKI), it is crucial
to study the effects of high-incidence complications on
survival, including hypophosphatemia. Unfortunately,
few epidemiologic data about renal replacement therapy
associated hypophosphatemia and global clinical out-
come have been reported to date.
In the present study, we retrospectively investigated a
critically ill patient cohort with AKI who received con-
tinuous veno-venous hemofiltration (CVVH) therapy to
determine whether hypophosphatemia during CVVH is
associated with mortality.
Materials and methods
This study was approved by the Institutional Ethics
Committee of Zhejiang University, and informed consent
was obtained from the patients and/or their guardians.
Patient selection
Between 1 January 2008 and 30 September 2011, about
6,000 critically ill patients brought to the ICU, emer-
gency ICU or surgical ICU at the First Affiliated Hos-
pital, College of Medicine, Zhejiang University, were
retrospectively reviewed. From among those patients,
760 individuals who were diagnosed as having AKI and
who were receiving CVVH therapy served as the patient
group for the present study. AKI was defined according
to the risk, injury, failure, loss, and end-stage kidney di-
sease (RIFLE) consensus criteria [21]. Patients who had
underlying phosphorus disturbances stemming from
premorbidity were not included in the study. Therefore,
patients with hypoparathyroidism, hyperparathyroidism,
chronic renal tubular defect, alcoholic ketoacidosis, dia-
betic ketoacidosis and persistent respiratory alkalosis
were excluded from the study.
Patient data
All patient data were abstracted from medical records as
well as from the linked clinical inspection database and
blood purification database at the hospital. We collected
the following demographic and clinical information of
the patients at the initiation of and during CVVH
therapy: age, gender, premorbidity, recent surgery, main
source of infection, Acute Physiology Chronic HealthEvaluation II (APACHE II) score at the initiation of
CVVH therapy, length of mechanical ventilation after
initiation of CVVH therapy, technical parameters and
duration of CVVH, phosphate supplementation and
daily serum phosphorus level. Serum phosphorus level
tests were performed at least once daily at 6:00 AM.
Therefore, the data from the 6:00 AM tests were adop-
ted to stand for the daily serum phosphorus levels.
Sodium glycerophosphate injection was applied to the
patients with hypophosphatemia according the drug
manufacturer’s instructions. The clinical principle of the
sodium glycerophosphate injection was to maintain the
serum phosphorus level at normal standard. Thereafter
phosphate supplementation would be sustained, unless
the maximum dose permitted by the drug manufac-
turer’s instructions was reached or hypophosphatemia
was corrected. All patients were treated with CVVH.
The Accura Hemofiltration System (Baxter Healthcare,
Deerfield, IL, USA) was used to administer CVVH the-
rapy. Polysulfone filters (AV600S Dialyzer; Fresenius
Medical Care, Bad Homburg, Germany) were used for
all patients, and the filter was changed when the trans-
membrane pressure (TMP) of the filter was greater than
250 mmHg. Central venous access was used with ca-
theters of 11.5Fr or 13.5Fr × 16 cm, 11.5Fr or 13.5Fr ×
19.5 cm (Kendall catheter; Tyco Healthcare Group,
Mansfield, MA, USA). Nonphosphate replacement fluid
was delivered into the extracorporeal circuit at a
predilution/postdilution ratio of 2:1. The prescribed
dose of CVVH (mean dose in first 72 hours) was
48.53 ml/kg/h. Anticoagulation was performed accor-
ding to each patient’s condition with unfractionated
heparin, low-molecular-weight heparin or heparin-free
anticoagulation.
Variables
As endpoints, we used death during the 28-day period
and survival at 28 days after initiation of CVVH. Hypo-
phosphatemia was defined according to the colorimetric
method as serum phosphorus level less than 0.81 mmol/L
(2.5 mg/dl), and severe hypophosphatemia was defined as
serum phosphorus level less than 0.32 mmol/L (1 mg/dl).
The ratio of CVVH therapy days with hypophosphatemia
to total CVVH therapy days was calculated to reflect the
persistence of hypophosphatemia.
Statistical analysis
Statistical analysis was performed using SPSS version
11.5 software (SPSS, Inc, Chicago, IL, USA). A P-value
less than 0.05 was considered statistically significant. A
univariate comparison was performed to compare var-
iables between two groups using an unpaired t-test for
continuous variables and a χ2 test or Fisher’s exact test
for categorical variables. The Cox proportional hazards
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contribution of prognostic factors to the prediction of
outcome at 28 days after initiation of CVVH therapy.
When constructing the multivariate model, univariate
factors with P-values less than 0.2 were used. The odds
ratios with 95% confidence intervals (CIs) were used to
estimate the association between the independent varia-
bles and the dependent variable.
Results
The baseline demographics and clinical characteristics of
the patients are summarized in Table 1. The mean age
(±SD) for patients of the study cohort was 59.72 ± 17.79
years, and 498 patients (65.5%) were male. A total of 406
patients (53.4%) were diagnosed with sepsis according to
the criteria published by the International Sepsis Defi-
nitions Conference [22]. The mean APACHE II score
(±SD) at the initiation of CVVH therapy was 21.04 ±
6.64. A total of 471 patients (62.0%) were injected with
sodium glycerophosphate according the manufacturer’sTable 1 Baseline demographic and clinical characteristics of t
Characteristics Patie
(N =
Mean age (yr) 59.
Male sex (%) 498 (








Recent surgery (%) 272 (
Sepsis (%) 406 (
Main source of infection (%)
Chest 233 (
Abdomen 118 (
Bloodstream, including line-related infection 36 (
Other or unknown source 19 (
APACHE II score (mean) 21.
Mean length of mechanical ventilation (days) 8.0
Prescribed dose of CVVH (mean in first 72 hours, ml/kg/h) 48.
Delivered dose of CVVH (median in first 72 hours, ml/kg/h) 41.
Therapeutic time of CVVH (days) 7.9
Phosphate supplementation (%) 471 (
Hypophosphatemia during CVVH (%) 521 (
Severe hypophosphatemia (%) 109 (
aAPACHE II, Acute Physiology Chronic Health Evaluation II; CVVH, continuous veno-vdrug instructions. A total of 521 patients (68.6%) had
hypophosphatemia episodes during CVVH therapy, and
109 patients (14.3%) developed severe hypophospha-
temia according to our definition. A total of 387 patients
(50.9%) were alive at day 28 after initiation of CVVH.
Univariate analysis indicated that survivors were signifi-
cantly different from nonsurvivors with regard to some
demographic and clinical characteristics, including youn-
ger age, less likely to have chronic ill health (as defined
by the APACHE II criteria), lower occurrence of sepsis,
lower APACHE II scores and lower occurrence of severe
hypophosphatemia (11.4% vs. 17.4%; P = 0.022). How-
ever, gender, recent surgery, median length of mechani-
cal ventilation after initiation of CVVH therapy, median
dose and therapeutic time of CVVH, the proportion
of patients receiving phosphate supplementation and
the occurrence of hypophosphatemia (67.2% vs. 70.0%;
P = 0.435) demonstrated no significance between the
survivor and nonsurvivor cohorts. Univariate factors
with P-values less than 0.2 included age, chronic illhe patientsa
nts Survivors Nonsurvivors P
760) (n = 387) (n = 373)
72 58.25 61.25 0.020
65.5) 250 (64.6) 248 (66.5) 0.594








35.8) 138 (35.7) 134 (35.9) >0.999
53.4) 188 (48.6) 218 (58.4) 0.010
57.3) 97 (51.6) 136 (62.4)
29.1) 62 (33.0) 56 (25.7)
8.9) 20 (10.6) 16 (7.3)
4.7) 9 (4.8) 10 (4.6)
04 19.42 22.72 <0.001
1 8.30 7.70 0.290
53 47.67 49.42 0.089
00 40.32 41.71 0.542
4 8.20 7.67 0.271
62.0) 248 (64.1) 223 (59.8) 0.232
68.6) 260 (67.2) 261 (70.0) 0.435
14.3) 44 (11.4) 65 (17.4) 0.022
enous hemofiltration. P-value represents live cohort vs. dead cohort.
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sence of severe hypophosphatemia episode during
CVVH therapy. These patients were included in the
Cox proportional hazards survival model to avoid the
potential influence of some confounding risk factors.
The multivariate analysis indicated that the occurrence
of severe hypophosphatemia episode during CVVH
therapy was dependent on outcome (P = 0.700), whereas
APACHE II score was independent of 28-day mortality
(Figure 1 and Table 2).
Thereafter we analyzed the subcohort of 521 pa-
tients who had developed hypophosphatemia during the
CVVH therapy period. In this cohort, the mean ratio of
CVVH therapy days with hypophosphatemia to total
CVVH therapy days was 0.58. Therefore, the ratio ≥0.58
was defined as a high ratio, and the ratio <0.58 was de-
fined as a low ratio. A total of 260 patients (49.9%) were
alive at day 28 after initiation of CVVH of this cohort,
and the univariate analysis indicated that survivors were
significantly different from nonsurvivors regarding some
factors, including younger age, less likelihood of chronic
ill health, a lower occurrence of sepsis, lower APACHE
II score and lower occurrence of high ratio of CVVH
therapy days with hypophosphatemia to total CVVH
therapy days (36.9% vs. 55.9%; P < 0.001) (Table 3).
However, gender, recent surgery, median length of me-
chanical ventilation after initiation of CVVH therapy,
median dose and therapeutic time of CVVH and propor-
tion of patients receiving phosphate supplementation
demonstrated no significance between the survivor andFigure 1 Cumulative survival rate curve of the Cox proportional haza
hypophosphatemia episodes during continuous veno-venous hemofiltratio
critically ill patients with acute kidney injury compared with those who didnonsurvivor cohorts (Table 3). Univariate factors with
P-values less than 0.2, including age, chronic ill health,
sepsis, APACHE II score and high or low ratio of CVVH
therapy days with hypophosphatemia to total CVVH
therapy days were recruited in the Cox proportional
hazards survival model and indicated that the ratio of
CVVH therapy days with hypophosphatemia to total
CVVH therapy days was independently associated with
mortality. Compared with the patients with a low ratio,
those with a high ratio conferred a 1.451-fold increase
in 28-day mortality rate (95% CI = 1.103 to 1.910;
P = 0.008) (Figure 2 and Table 4). Meanwhile, APACHE II
score was also an independent factor associated with
28-day mortality.
Discussion
AKI is a frequent problem in the ICU associated with
substantial morbidity, mortality and healthcare expendi-
tures. Severe AKI is always accompanied by dysfunction
in other organs and is characterized by high mortality.
Renal replacement therapy remains the cornerstone of
supportive care [23]. To date, some important issues re-
garding renal replacement therapy are still unclear, and
any progress regarding interventions may contribute
much to the global outcomes of these critically ill pa-
tients. Therefore, in our present study, patients diag-
nosed with AKI receiving CVVH therapy were recruited
as the study cohort to determine the relationship of
clinical outcomes and hypophosphatemia, one of the fre-
quently complications of renal replacement therapy.rds survival model. The curve indicates that the occurrence of severe
n (CVVH) did not significantly increase the 28-day mortality rate of
not develop severe hypophosphatemia (P = 0.700).
Table 2 Variables included in the Cox proportional
hazards survival model and hazard ratiosa
Characteristics Odd ratio (95%
confidence interval)
P
Age 1.001 (0.994 to 1.008) 0.749
Presence of chronic ill health 1.211 (0.941 to 1.558) 0.137
APACHE II score 1.058 (1.041 to 1.076) <0.001
Presence of sepsis 1.015 (0.806 to 1.279) 0.896
Presence of severe hypophosphatemia
episode during CVVH therapy
0.943 (0.699 to 1.272) 0.700
aAPACHE II, Acute Physiology Chronic Health Evaluation II; CVVH, continuous
veno-venous hemofiltration.
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main causes of hypophosphatemia in critically ill patients
may include severe infection, trauma, postoperative state
and malnutrition [6]. Indeed, in the present study, 272 pa-
tients (35.8%) had received surgical interventions and 406Table 3 Baseline demographic and clinical characteristics of t
















Bloodstream, including line-related infection
Other or unknown source
APACHE II score (mean)
Length of mechanical ventilation (days)
Prescribed dose of CVVH (mean in first 72 hours, ml/kg/h)
Delivered dose of CVVH (median in first 72 hours, ml/kg/h)
Therapeutic time of CVVH (days)
Phosphate supplementation (%)
Ratio of CVVH therapy days with hypophosphatemia to total CVVH therapy days
High ratiob (%)
Low ratioc (%)
a Acute Physiology Chronic Health Evaluation II; CVVH, continuous veno-venous hem
the ratio of CVVH therapy days with hypophosphatemia to total CVVH therapy days
hypophosphatemia to total CVVH therapy days <0.58.patients (53.4%) were diagnosed with sepsis. Therefore,
hypophosphatemia may occur in some patients before the
initiation of CVVH therapy because of the illness itself.
Importantly, the potential that hypophosphatemia could
be a surrogate marker for something else can never be ex-
cluded, even during the CVVH therapy period.
It was reported in the ATN Study that the incidence of
hypophosphatemia was 10.9% in the low-intensity group
and 17.6% in the high-intensity group [20]. In the RENAL
Trial, the incidence of hypophosphatemia in the low- and
high-intensity groups was 54.0% and 65.1%, respectively
[19]. The difference in hypophosphatemia incidence may
due to the following causes. The modality of renal replace-
ment therapy performed in the ATN Study included inter-
mittent hemodialysis, sustained low-efficiency dialysis and
continuous veno-venous hemodiafiltration. In the RENAL
Study only continuous veno-venous hemodiafiltration was
administered. The therapeutic dose of renal replacementhe patients who developed hypophosphatemia during
Patients Survivors Non-survivors P
(N = 521) (n = 260) (n = 261)
60.34 57.97 62.71 0.002
326 (62.6) 163 (62.7) 163 (62.5) >0.999








209 (40.1) 104 (40.0) 105 (40.2) 0.929
304 (58.3) 137 (52.7) 167 (64.0) 0.016
177 (58.2) 68 (49.6) 109 (65.3)
92 (30.3) 51 (37.2) 41 (24.6)
25 (8.2) 13 (9.5) 12 (7.2)
10 (3.3) 5 (3.6) 5 (3.0)
20.86 19.32 22.44 <0.001
9.56 9.68 9.44 0.700
50.78 50.12 51.43 0.272
42.23 41.78 42.68 0.235
9.49 9.60 9.37 0.710
355 (68.1) 175 (67.3) 180 (69.0) 0.707
(mean) 0.58 0.50 0.65 <0.001
242 (46.4) 96 (36.9) 146 (55.9)
279 (53.6) 164 (63.1) 115 (44.1)
ofiltration. P value represents live cohort vs. dead cohort. bHigh ratio means
≥0.58. cLow ratio means the ratio of CVVH therapy days with
Figure 2 Cumulative survival rate curve of the Cox proportional hazards survival model. The survival curve indicates that patients with a
high ratio of continuous veno-venous hemofiltration (CVVH)therapy days with hypophosphatemia to total CVVH therapy days (ratio ≥ 0.58) had
an increased 28-day mortality rate compared with those with a low ratio (ratio < 0.58) during CVVH therapy (P = 0.008).
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the RENAL Trial (35 ml/kg/h vs. 40 ml/kg/h in the high-
intensity group). The results of comparison of the two
study implied that phosphate clearance on continuous
veno-venous hemodiafiltration might be significantly grea-
ter than intermittent hemodialysis because of ongoing
intercompartmental mass transfer and larger filter pore
size. In the present study, the modality of renal replace-
ment therapy was CVVH, the mean therapeutic dosage
was closer to that used in the RENAL Trial design, and
the incidence of CVVH-associated hypophosphatemia ac-
cording to our data was also similar to the RENALTrial.
Hypophosphatemia can be caused by decreasing absorp-
tion, increasing renal excretion or internal redistribution
of inorganic phosphate. In critically ill patients, inorganicTable 4 Variables included in the Cox proportional
hazards survival model and hazard ratios of patients who
developed hypophosphatemia during the continuous
veno-venous hemofiltration therapy perioda
Characteristics Odd ratio (95%
confidence interval)
P
Age 1.004 (0.995 to 1.013) 0.373
Presence of chronic ill health 1.284 (0.946 to 1.742) 0.109
APACHE II score 1.051 (1.029 to 1.073) <0.001
Presence of sepsis 1.049 (0.788 to 1.396) 0.742
Presence of high ratiob 1.451 (1.103 to 1.910) 0.008
aAcute Physiology Chronic Health Evaluation II. bA high ratio means the ratio
of continuous veno-venous hemofiltration (CVVH) therapy days with
hypophosphatemia to total CVVH therapy days ≥0.58.phosphate redistribution across the cell membrane is a
common phenomenon [24]. Therefore, serum phosphorus
levels do not accurately reflect total body phosphorus
stores, and this bias can be aggravated by CVVH therapy
because of the quick serum phosphorus clearance during
the intervention. The ratio of CVVH therapy days with
hypophosphatemia to total CVVH therapy days was calcu-
lated in the present study to avoid the bias of the serum
phosphorus test. The present study showed that a single
test of serum phosphorus concentration could not serve
as an independent factor predictive of mortality even if it
reached the standard of severe hypophosphatemia. Inter-
estingly, the ratio of CVVH therapy days with hypophos-
phatemia to total CVVH therapy days was proved to be a
factor independent of the global clinical outcome through
the multivariate analysis, indicating that a high ratio con-
ferred a higher 28-day mortality rate. The results sug-
gested that the persistence of hypophosphatemia had the
potential to harm critically ill patients. Once hypophos-
phatemia happens, the therapeutic strategy might be ad-
justed, including more phosphate supplementation as well
as regulation of renal replacement dosage or modality, to
avoid persistence of hypophosphatemia.
To date, whether the impact of intensity or dosage of
renal replacement therapy is crucial to the outcomes of
critically ill patients is controversial. Despite the bene-
fits of high-intensity renal replacement therapy, including
superior hemodynamic stability, metabolic clearance
and volume control, no survival advantage can be de-
monstrated with its use [25]. Although study design
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plausible that the complications of the high-intensity
renal replacement therapy offset its potential benefits
in critically ill patients. Unfortunately, some outcome–
dose studies have not even discussed adverse effects. In
our data, normal phosphate supplementation treatment
failed to reverse hypophosphatemia during CVVH be-
cause the majority of the patients with hypophosphatemia
(68.6%) received regular sodium glycerophosphate injec-
tions. Thus, a new strategy should be adopted to resolve
this clinical problem. The present study highlights the
need for analysis of adverse effects and clinical strategies
to correct hypophosphatemia during CVVH therapy, in-
cluding phosphate supplementation, especially the use of
phosphate-containing replacement fluid to decrease the
high mortality rate of severe AKI patients [17,18,26].
The present study has several limitations. The retro-
spective study design decreased the power of the con-
clusions. As the endpoints we adopted, we dealt with the
28-day mortality in the present study, which was only a
surrogate outcome. In addition, various clinical settings
may lead to hypophosphatemia in critically ill patients, so
we could never exclude the potential that hypophospha-
temia could be a surrogate marker for something other
than CVVH. A prospective study with various days to
mortality may resolve this bias.
Conclusions
We retrospectively investigated a critically ill patient co-
hort with AKI receiving CVVH therapy and found that
hypophosphatemia during CVVH was associated with
28-day mortality. The ratio of CVVH therapy days with
hypophosphatemia to total CVVH therapy days was in-
dependently associated with the global outcome. Com-
pared with the patients with low ratios, those with high
ratios had a 1.451-fold increase in 28-day mortality rate
(95% CI = 1.103 to 1.910; P = 0.008). This conclusion
implies that the persistence of hypophosphatemia risks
potential harm to critically ill patients. Once hypophos-
phatemia happened, the therapeutic strategy might be
adjusted to avoid its persistence.
Key messages
 Hypophosphatemia during CVVH was associated
with the global clinical outcome of critically ill
patients with AKI.
 The ratio of CVVH therapy days with
hypophosphatemia to total CVVH therapy days was
independently associated with 28-day mortality.
 A high ratio of CVVH therapy days with
hypophosphatemia to total CVVH therapy days
conferred a higher mortality rate among critically ill
patients with AKI.Abbreviations
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TMP: Transmembrane pressure.
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